# TherapeuticsMD, Inc. (TXMD)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $21M  
**Price:** $1.82 (-2.15%)

> TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally. The company’s primary role is to develop and license differentiated therapies that address conditions associated with menopause, contraception, and related gynecologic needs. Through licensing agreements, TherapeuticsMD grants commercial rights to partners such as Mayne Pharma for products including hormone therapy and contraceptive offerings, while retaining economic interests via royalties. Its portfolio is complemented by vitamin and prenatal brands historically developed through its VitaMed business, aimed at obstetric and gynecologic practices. By concentrating on proprietary formulations and lifecycle management rather than large-scale sales infrastructure, TherapeuticsMD, Inc. positions itself as an asset-light participant in the pharmaceutical value chain, contributing specialized products to the broader women’s healthcare market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3M | — | -$4M | -$569,000 | — |
| 2024 | $2M | — | -$6M | -$2M | — |
| 2023 | $1M | $1M | -$9M | -$10M | — |
| 2022 | $70M | $69M | $1M | $112M | — |
| 2021 | $3M | $1M | -$80M | -$172M | — |
| 2020 | $65M | $49M | -$156M | -$184M | — |
| 2019 | $50M | $43M | -$151M | -$176M | — |
| 2018 | $16M | $13M | -$130M | -$133M | — |
| 2017 | $17M | $14M | -$78M | -$77M | — |
| 2016 | $19M | $15M | -$90M | -$90M | — |
| 2015 | $20M | $16M | -$85M | -$85M | — |
| 2014 | $15M | $11M | -$54M | -$54M | — |
| 2013 | $9M | $7M | -$26M | -$28M | — |
| 2012 | $4M | $2M | -$16M | -$35M | — |
| 2011 | $2M | $1M | -$5M | -$13M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $38M | $11M | $27M | — | — |
| 2024 | $39M | $11M | $27M | $5M | — |
| 2023 | $43M | $14M | $29M | $4M | — |
| 2022 | $90M | $55M | $35M | — | — |
| 2021 | $169M | $263M | -$94M | — | $188M |
| 2020 | $182M | $306M | -$124M | — | $238M |
| 2019 | $266M | $257M | $9M | — | $195M |
| 2018 | $212M | $114M | $98M | — | $73M |
| 2017 | $143M | $13M | $130M | — | — |
| 2016 | $142M | — | $127M | — | — |
| 2015 | $74M | $11M | $63M | — | — |
| 2014 | $59M | $11M | $48M | — | — |
| 2013 | $62M | $7M | $55M | — | — |
| 2012 | $6M | $7M | -$1M | — | — |
| 2011 | $1M | $3M | -$2M | $126,421 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2021 | -$143M | $34,000 | -$143M |
| 2020 | -$159M | $207,000 | -$160M |
| 2019 | -$166M | $2M | -$168M |
| 2018 | -$107M | $217,040 | -$107M |
| 2017 | -$76M | $61,817 | -$76M |
| 2016 | -$69M | $396,154 | -$70M |
| 2015 | -$79M | $165,257 | -$79M |
| 2014 | -$46M | $30,962 | -$46M |
| 2013 | -$21M | $40,790 | -$21M |
| 2012 | -$13M | $66,405 | -$13M |
| 2011 | -$5M | $28,766 | -$5M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TXMD)